JANUMET Drug Patent Profile

Which patents cover Janumet, and when can generic versions of Janumet launch?

Janumet is a drug marketed by Msd Sub Merck and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-one patent family members in forty countries.

The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Janumet

Janumet was eligible for patent challenges on October 16, 2010.

Annual sales in 2022 were $1.6bn, indicating a strong incentive for generic entry (peak sales were $2.6bn in 2020).

There have been thirty-eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for JANUMET

International Patents:	61
US Patents:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	8
Clinical Trials:	20
Drug Prices:	Drug price information for JANUMET
Drug Sales Revenues:	Drug sales revenues for JANUMET
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JANUMET
What excipients (inactive ingredients) are in JANUMET?	JANUMET excipients list
DailyMed Link:	JANUMET at DailyMed

See drug prices for JANUMET

See drug sales revenues for JANUMET

Recent Clinical Trials for JANUMET

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Galenicum Health	Phase 1
Eva Pharma	Phase 1
Genuine Research Center, Egypt	Phase 1

See all JANUMET clinical trials

Pharmacology for JANUMET

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Paragraph IV (Patent) Challenges for JANUMET

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JANUMET	Tablets	metformin hydrochloride; sitagliptin phosphate	50 mg/500 mg and 50 mg/1000 mg	022044	5	2010-10-18

US Patents and Regulatory Information for JANUMET

JANUMET is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007	AB	RX	Yes	Yes					Y
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012		RX	Yes	No					Y
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007	AB	RX	Yes	No					Y
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007	AB	RX	Yes	Yes					Y
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007	AB	RX	Yes	No					Y

Expired US Patents for JANUMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-001	Mar 30, 2007

International Patents for JANUMET

See the table below for patents covering JANUMET around the world.

Country	Patent Number	Title	Estimated Expiration
Luxembourg	91334
Ukraine	74912	BETA-AMINOTETRAHYDROIMIDAZO-(1,2-A)-PYRAZINES AND TETRATRIAZOLO-(4,3-A)-PYRAZINES AS INHIBITORS OF DIPEPTYLPEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES
Denmark	1084705
Spain	2259713
New Zealand	332707	USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS (DPIV) FOR LOWERING THE BLOOD GLUCOSE LEVEL IN MAMMALS

Supplementary Protection Certificates for JANUMET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0896538	08C0008	France		PRODUCT NAME: VILDAGLIPTINE OU UN DE SES SELS PHARMACETIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/07/414/001 DU 20070926; REGISTRATION NO/DATE AT EEC: EU/1/07/414/001-017 DU 20070926
1412357	C300287	Netherlands		PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER SITAGLIPTINE FOSFAAT MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321
2498758	LUC00152	Luxembourg		PRODUCT NAME: METFORMINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; SAXAGLIPTINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; DAPAGLIFLOZINE OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1401 20191113
1084705	PA2014043	Lithuania		PRODUCT NAME: SAXAGLIPTINUM; REGISTRATION NO/DATE: EU/1/09/545/001-015 20091001
1412357	132008901682802	Italy		PRODUCT NAME: SITAGLIPTIN/METFORMINA CLORIDRATO(JANUMET, VELMETIA, EFFICIB); AUTHORISATION NUMBER(S) AND DATE(S): JANUMET:EU/1/08/455/001... 014; VELMETIA:EU/1/08/456/001...014;EFFICIB: EU/1/08/457/001....014, 20080716;58450-01;58450-02; 58450-03, 20080408

Market Dynamics and Financial Trajectory for JANUMET

Last updated: February 19, 2026

What is JANUMET?

JANUMET is a combination drug containing sitagliptin and metformin, approved for type 2 diabetes management. It was developed by Merck & Co. and marketed globally. It integrates a dipeptidyl peptidase-4 (DPP-4) inhibitor with a biguanide, combining mechanisms to improve glycemic control.

Market Size and Growth Drivers

The global type 2 diabetes treatment market reached $54 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 7.4% to $85 billion by 2028.[1] Key factors include rising prevalence, aging populations, and increased focus on combination therapies.

Prevalence and Patient Base

• World prevalence of type 2 diabetes was approximately 462 million in 2019, expected to rise to 700 million by 2045.[2]
• The U.S. accounts for over 34 million diagnosed cases, with annual new diagnoses exceeding 1 million.[3]
• Growing demand for effective oral therapies supports market expansion.

Competition

Major competitors include:

• Tradjenta (linagliptin) by Boehringer Ingelheim
• Jardiance (empagliflozin) by Lilly/Bayer (SGLT2 inhibitors)
• Glucophage (metformin) as a monotherapy

JANUMET holds significant market share due to its combination formulation, which improves adherence and reduces pill burden.

Revenue and Market Share

• Merck reported global sales of JANUMET at approximately $2.2 billion in 2022.[4]
• The Americas region accounts for 70% of sales, with steady growth.
• In Europe and Asia-Pacific, sales are growing as prescriptions expand.

Pricing and Payer Landscape

• The average wholesale price (AWP) in the U.S. is about $400 per month per patient.
• Insurance coverage and formularies influence patient access, with payers favoring combination drugs for their adherence benefits.

Patent and Regulatory Status

• JANUMET's initial U.S. patent expired in 2017.
• Merck secured additional patents on formulations and methods of use extending protection until 2025–2030.[5]
• Generic versions entered markets in some regions post-patent expiry, affecting revenue.

R&D and Pipeline

• Merck has investigated JANUMET's use in combination with other agents, including SGLT2 inhibitors and GLP-1 receptor agonists.
• The company's pipeline includes next-generation DPP-4 inhibitors with improved efficacy and fewer side effects.

Market Trends Impacting JANUMET

1. Shift Toward SGLT2 and GLP-1 Therapies: Increased use of SGLT2 inhibitors and GLP-1 receptor agonists for cardiovascular and renal benefits.
2. Pricing and Reimbursement Pressure: Payer push for cost-effective therapies pressures margins.
3. Generic Competition: Post-patent expiry generic drugs reduce prices and sales volume.
4. Regulatory Changes: Evolving guidelines favor newer, more effective agents, risking market share for older drugs.

Financial Trajectory Outlook

Year	Estimated Global Sales	Notes
2023	$2.1 billion	Slight decline due to generic competition
2024	$1.9 billion	Continued erosion from generics and market shifts
2025	$1.7 billion	Patent expiration impacts sales
2026	$1.5 billion	Market share stabilizes with new formulations
2027	$1.4 billion	Marginal decline as newer therapies dominant

Strategic Factors

• Launch of reformulated versions or fixed-dose combinations with newer agents could stabilize revenues.
• Expansion into emerging markets remains crucial for growth.
• Market penetration depends on collaborations with payers and healthcare providers.

Key Takeaways

• JANUMET remains a significant revenue generator for Merck, but faces declining sales post-patent expiry.
• Competition from monotherapies, generics, and newer drug classes impacts market share.
• Global diabetes prevalence and ongoing need for combination therapies support long-term demand.
• Future growth hinges on innovation, pipeline expansion, and geographic market diversification.

FAQs

Q1: How will patent expiry affect JANUMET revenues?
A: Patent expiry in 2017 led to generic competition, causing a sales decline. Merck's additional patents extend exclusivity until approximately 2025–2030, which temporarily sustains revenue.

Q2: What are the main competitors of JANUMET?
A: Tradjenta, Jardiance, and generic metformin are key competitors, with newer classes like SGLT2 inhibitors and GLP-1 receptor agonists gaining market share.

Q3: How does pricing influence JANUMET's market position?
A: The drug's premium pricing is offset by adherence benefits; however, pricing pressures from payers and generics impact margins.

Q4: What market trends threaten JANUMET's prospects?
A: Growing preference for newer therapies with cardiovascular and renal benefits, patent expirations, and reimbursement shifts.

Q5: What strategies could extend JANUMET’s market viability?
A: Developing combination formulations with novel agents, expanding in emerging markets, and optimizing cost-effectiveness.

---

References

[1] MarketsandMarkets. (2022). Diabetes Therapeutics Market.
[2] International Diabetes Federation. (2019). IDF Diabetes Atlas, 9th Edition.
[3] CDC. (2020). National Diabetes Statistics Report.
[4] Merck & Co. Annual Report. (2022).
[5] U.S. Patent and Trademark Office. (2020). Patent filings on JANUMET formulations and methods.